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Abstract
Background: Infantile hemangiomas (IH) are the most common benign tumors of infancy. The typical clinical
course consists of rapid growth during the first year of life, followed by natural and gradual involution over a
multi-year time span through unknown cellular mechanisms. Some tumors respond to medical treatment with
corticosteroids or beta-blockers, however, when this therapy fails or is incomplete, surgical extirpation may be
necessary. Noninvasive therapies to debulk or eliminate these tumors would be an important advance. The
development of an in vitro cell culture system and an animal model would allow new insights into the biological
processes involved in the development and pathogenesis of IH.
Results: We observed that proliferative stage IH specimens contain significantly more SALL4+ and CD133+ cells
than involuting tumors, suggesting a possible stem cell origin. A tumor sphere formation assay was adapted to
culture IH cells in vitro. Cells in IH tumor spheres express GLUT1, indicative of an IH cell of origin, elevated levels of
VEGF, and various stem/progenitor cell markers such as SALL4, KDR, Oct4, Nanog and CD133. These cells were able
to self-renew and differentiate to endothelial lineages, both hallmarks of tumor stem cells. Treatment with
Rapamycin, a potent mTOR/VEGF inhibitor, dramatically suppressed IH cell growth in vitro. Subcutaneous injection
of cells from IH tumor spheres into immunodeficient NOD-SCID mice produced GLUT1 and CD31 positive tumors
with the same cellular proliferation, differentiation and involution patterns as human hemangiomas.
Conclusions: The ability to propagate large numbers of IH stem cells in vitro and the generation of an in vivo
mouse model provides novel avenues for testing IH therapeutic agents in the future.
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Background
Infantile hemangiomas are benign tumors whose prolif-
erative phase during the first year of life is characterized
by a rapid outgrowth of vascular endothelial cells. An
involuting phase then occurs lasting up to 10 years with
replacement of vascular tissues by fibrofatty tissues[1-4].
Clinically, most hemangiomas present few serious health
problems. In some cases, they may be extremely
disfiguring, impede vision, cause airway obstruction or
congestive heart failure [5-7]. Traditionally, medical
therapy for IH involved the use of topical, intralesional
or systemic corticosteroids. This has now largely been
replaced by beta-blockers. When medical therapy fails
or is incomplete, surgical resection is necessary [8,9].
Depending on the patient’s age and degree of surgical
resection, these vascular tumors may recur at the same
location[10]. This suggests either incomplete surgical
resection or the presence of a population of tumor stem
cells that is responsible for recurrence[11]. The isolation
of IH stem cells using anti-CD133 antibodies and
immunomagnetic techniques was recently reported [12].
Transplantation of these cells into nude mice produced
* Correspondence: to@vbiny.org; wanermd@chpnet.org; yupo.
ma@stonybrook.edu
† Contributed equally
1Department of Pathology, SUNY at Stony Brook, Stony Brook, NY 11794,
USA
2Vascular Birthmark Institute of New York, New York, NY 10023, USA
Full list of author information is available at the end of the article
Xu et al. Journal of Hematology & Oncology 2011, 4:54
http://www.jhoonline.org/content/4/1/54 JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2011 Xu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.tumors that were composed of endothelial cells and
blood vessels. However, while the formation of blood
vessels was followed by involution and fibrofatty tissue
production, no obvious proliferative phase was observed.
In the study reported herein, the isolation of IH stem
cells was accomplished using growth in selective culture
media. These cells form tumor spheres that express CD133
[13,14] and other stem/progenitor cell markers and possess
self-renewal capabilities. The tumor sphere cells can be dif-
ferentiated to GLUT1-expressing cells (indicative of an IH
cell origin) [15-17] by exposure to VEGF.
By multiplex Luminex analysis, we demonstrated that
a specific growth factor, VEGF, is secreted from the IH
tumor spheres and that an mTOR/VEGF inhibitor,
Rapamycin, dramatically inhibits IH tumor stem cell
growth. Furthermore, when cells from tumor spheres
are injected into nude mice, they recapitulate human IH
tumors, exhibiting characteristic proliferative and invo-
luted phases.
Methods
Patient Samples
Infantile hemangioma tissues were obtained with
approval of Yale University Institutional Review Board
and all participants gave informed written consent.
Immunohistochemical staining
Staining was performed according to standard techni-
ques as previously reported [18].
IH Tumor Sphere Culture
Post-operative IH tissue samples were washed using PBS
and transferred into a sterile Petri dish. The tissue was
minced into a fine paste (1 × 1 mm
2) and washed with
PBS again. IH tissues were then digested with 2 mg/ml
collagenase (Invitrogen, CA) for at least 2 hours shaking at
37°C. The cells were dispersed by repeat passage through
a pipette tip and filtration through a 100 μM nylon cell
strainer. Cells were plated on low attachment Petri dish at
ad e n s i t yo f2×1 0
5 cells/ml using a stem cell culture
(SCC) media (all ingredients from Invitrogen, CA) consist-
ing of Knockout DMEM, 15% Knockout Serum Substitute,
1x non-essential amino acids (NEAA), and 20 ng/ml of
both basic fibroblast growth factor (bFGF) and human
endothelial growth factor (hEGF). Tumor spheres were
passaged approximately every seven days (roughly 200
cells/sphere); spheres werew a s h e do n c ew i t hP B Sa n d
then single cell suspension made by incubation with 2 mg/
ml collagenase IV at 37°C for 10 minutes.
Differentiation of IH Tumor Spheres
Tumor spheres were transferred to gelatin coated dishes
to attach and were differentiated using IH differentiation
medium containing Knockout DMEM, 15% Knockout
Serum Substitute, 1x non-essential amino acids (NEAA),
20 ng/ml each of basic fibroblast growth factor (bFGF),
20 ng/ml human endothelial growth factor (hEGF), and
50 ng/ml vascular endothelial growth factor (VEGF)
(R&D Minneapolis MN).
Immunofluorescent staining
Cells were fixed with 4% freshly prepared paraformalde-
hyde for 15 minutes. Following three washes, the cells
were blocked with 5% bovine serum albumin (BSA) in
1x phosphate buffered saline-Triton X-100 (TPBS) for 1
h at room temperature. Primary antibodies [mouse anti-
GLUT1 (1:80 Abcam, Cambridge, MA), rabbit anti-
G L U T 1( 1 : 8 0 ,A b c a m ,C a m b r i d g e ,M A ) ,r a b b i ta n t i -
mouse FDR (1:50, Alpha Diagnostic International, San
Antonio, TX), rat-anti-mouse CD31 (1:25 BD Bios-
ciences, San Jose, CA), rabbit anti-CD133 (1:25 Biocare
Medical, Concord, CA) or rabbit anti-SALL4 (1:400;
developed by this laboratory)] in TPBS/1% BSA were
added to the tissue sections and the slides were incu-
bated at 4°C overnight. Following a wash with TPBS, an
appropriate secondary antibody [goat anti-rabbit-FITC
(SouthernBiotech, Birmingham, AL), goat anti-rabbit-
RPE (SouthernBiotech, Birmingham, AL), donkey anti-
mouse-Rhodamine (Chemicon, Temecula, CA), or don-
key anti-mouse-FITC (Sigma, Louis, MO)] was added
and the slides were incubated at room temperature for
2 h in the dark. After another three washes with TPBS,
the cells were counterstained with 50 ng/ml 4’, 6-diami-
dino-2-phenylindole (DAPI) for 10 minutes.
Measurement of growth factor secretion from tumor
spheres
Tumor spheres were cultured in stem cell culture media
for 15 days. The conditioned media, which had been
exposed to the tumor cells for 5, 10 and 15 days, was col-
lected and analyzed for the levels of the growth factors
(VEGF, EGF, FGF basic and G-CSF) using the human
growth factor (GF)4-Plex kit (Invitrogen, Carlsbad, CA)
and following manufacture’s recommended protocol.
Rapamycin, a potent mTOR/VEGF inhibitor, suppresses
proliferation of IH tumor stem cells in vitro
Tumor spheres were seeded onto Petri dishes and
exposed to 1 nM, 2 nM, and 4 nM Rapamycin in stem
cell culture media (see Methods, IH Tumor Sphere Cul-
ture) for 10 days. Approximately 30 tumor spheres were
collected at each time point (0, 3, 6 and 10 days), disso-
ciated by collagenase IV to single cells and counted for
cell numbers. Each sample was assayed in triplicate.
Mouse model
IH tumor spheres cultured for one week were disso-
ciated by collagenase to single cells and resuspended in
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6 cells per ml. 200
μl( 1 0
6 cells) was injected subcutaneously in both sides
of flanks of immunodeficient NOD/SCID mice. Matrigel
with PBS or 0.9% NaCl (without tumor cells) was
injected into two additional subcutaneous sites as a con-
trol. After 10, 20 and 30 days, the mice were sacrificed,
the tumor tissues excised, and fixed in formalin. Some
t i s s u es e c t i o n sw e r es t a i n e dwith standard hematoxylin
and eosin (H & E). Other IH tissue sections were ana-
lyzed using anti-Glut1 antibody and anti-CD31, a
human endothelial cell marker, for their expression
levels.
Results
Isolation and in vitro culture of hemangioma stem cells
Until now, there has been no adequate in vivo model to
evaluate novel therapeutic modalities for IH. The ability
to culture IH specimens would be an extremely valuable
translational research tool. Recently, Khan and collea-
gues described an hemangioma stem cell population
that expressed CD133 and, when transplanted into nude
mice, produced tumors that shared many characteristics
of hemangiomas but lacked an obvious proliferative
stage[12].
Our group and others [19,20] have previously shown
that mouse SALL4 plays an essential role in maintaining
the self-renewal and pluripotent properties of embryonic
stem (ES) cells and in governing the fate of the inner
cell mass through transcriptional modulation of Oct4
(also known as Pou5f1) and Nanog [19-24]. We have
also observed expression of SALL4 in hematopoietic
stem cells suggesting a role in stem cells of various
organ systems [25,26]. Very recently, we demonstrate
that SALL4 acts as a robust stimulator for both human
and mouse hematopoietic stem/progenitor cell ex vivo
proliferation [27-29]. We have hypothesized that IHs are
a stem cell disease and sought to determine if IHs
express either SALL4 and/or CD133. By flow cytometry
assay, it was shown that the proliferative IHs expressed
both markers either alone or together (data not shown).
Indeed, using immunohistochemistry, we observed sig-
nificantly more cells expressing SALL4 and CD133 in
proliferative IHs than in involuting phase IHs (Figure 1).
This supports the hypothesis that IHs may involute
because of depletion of stem cells or endothelial pro-
genitor cell populations.
We next sought to establish an in vitro culture system
to study the proliferation of IHs. Primary surgical speci-
mens were dissociated and plated on Petri dishes in
serum-free media. Mature endothelial cells and fibro-
blasts were unable to survive in these conditions. How-
ever, structures resembling the tumor spheres of other
tumor types were able to grow as shown in Figure 1, 1.
Tumor spheres derived from IH samples could be
cultured for prolonged periods of time (currently up to
passage 30). In addition, IH tumor spheres could also be
expanded into high density cultures (Figure 1) - an
advantageous feature for therapeutic uses. The IH
tumor spheres also resembled induced pluripotent (iPS)
stem cells that have been generated from fibroblasts in
our laboratory (Figure 1, 1), and also express SALL4.
This suggests that the tumor spheres may contain stem
cells.
Characterization of IH tumor spheres
N e x t ,w ew a n t e dt oe n s u r et h a ts p h e r e sf o r m e di no u r
assay were enriched for stem/progenitor cell markers
and that IHs were the cell of origin. As shown in Figure
2 and 2, these spheres were positive when immunos-
tained with antibodies against human stem cell markers,
SALL4 and CD133, and FDR (an early marker for
endothelial cell precursors) as well as an IH signature
marker, GLUT1. These data suggest that IH tumor
spheres are enriched for stem cells or progenitor cells
and that they express markers for early endothelial dif-
ferentiation and are derived from IH tissue.
Since IH tumor spheres express markers for immature
cell lineages and they are the IH cell of origin, we
sought to examine if tumor spheres bear the stem cell
properties of self renewal and differentiation. Following
the preparation of single cell suspensions, replating of
single cells from tumor spheres gave rise to secondary
tumor spheres within 3 to 4 days. The process of disso-
ciation to single cells was repeated and the formation of
tertiary tumor spheres was observed (Figure 3 and 3)
and tumor spheres could be passaged for prolonged per-
iods of time (currently up to passage 30). This suggests
that tumor spheres are able to self renew in the absence
of differentiation signals. When tumor spheres were cul-
tured in media favoring endothelial differentiation using
VEGF, they would adhere and differentiate toward an
endothelium- like morphology (Figure 3 and 3). The dif-
ferentiating tumor spheres continually expressed
GLUT1 (Figure 3). Expression of an endothelial marker,
CD31, increased from day 3 to day 12 and expression of
CD133 decreased over the samet i m ep e r i o d( F i g u r e3 ) .
This data illustrates that tumor spheres derived from IH
tissues have stem cell properties and supports the
hypothesis that IH is a stem cell disease.
Tumor spheres specifically secrete VEGF (vascular
endothelial growth factor)
Studies have indicated that tumor stem cells often con-
tribute to or are associated with a microenvironmental
niche. Understanding this process may allow develop-
ment of a tumor stem cell therapy. We measured the
concentration of growth factors, VEGF, EGF, FGF basic
and G-CSF, in tumor sphere culture media at different
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Page 3 of 11Figure 1 Expression of SALL4 and CD133 in IH tissues. (A) Immunohistochemistry staining of proliferative (1,3) and involuting (2,4) IH tissue
sections with anti-SALL4 and CD133 antibodies. Magnification: 100x, inset 200x. (B) 1, Phase contrast image of IHs tumor spheres forming on
Petri dishes with surrounding mature endothelial cells and/or fibroblasts. This was observed after 3 days of culture in serum-free media.
Magnification: 100 ×. 2, the tumor spheres continue to grow under serum-free conditions while mature cells such as endothelial cells and
fibroblasts do not. Magnification: 100x. 3, phase contrast image of high density tumor spheres in culture. Magnification: 100 ×. 4, comparison of
IH tumor sphere (left) and induced pluripotent stem cell clone (right). Magnification: 100 ×.
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Page 4 of 11Figure 2 Immunostaining of IH tumor spheres. (A) Immunostaining of IH tumor spheres with antibodies specific for SALL4, FDR (top) and
GLUT1 (bottom). Tumor spheres expressed these three markers. Mature cells surrounding tumor spheres were negative for SALL4 and FDR.
Magnification: 100 ×. (B) Immunostaining of IH tumor sphere and differentiating tumor sphere with an anti-CD133 antibody. The anti-CD133
reacted specifically with tumor spheres but not differentiated cells. Magnification: 100 ×.
Xu et al. Journal of Hematology & Oncology 2011, 4:54
http://www.jhoonline.org/content/4/1/54
Page 5 of 11Figure 3 Characterization of IH tumor spheres. (A) Determination of the self renewal and differentiation capabilities for IH tumor spheres. 1)
Dissociation of secondary tumor spheres to single cell colonies. 2) Tertiary tumor sphere formed from a single cell of a dissociated secondary
tumor sphere. 3) Phase contrast image of differentiating tumor sphere in the presence of VEGF and its spider like morphology exhibited after 24
hours. 4) Tumor spheres differentiating into endothelial like structures after 5 to 6 days of culture in the presence of VEGF. Magnification: 100x.
(B) Immunostaining of differentiating tumor spheres over time with anti-GLUT1 and anti-CD133 antibodies (top panel). The bottom panel
represents fully differentiated tumor spheres. Magnification: 100 ×.
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Page 6 of 11time points (Figure 4). The level of the growth factors in
the media was set as a background (blank). These values
were automatically deducted by the software from the
concentrations of the growth factors which were mea-
sured in the samples of interest. The concentrations
were derived from the measured level of fluorescence in
the samples by comparison with the fluorescence of the
standard curve of known concentrations. The values for
EGF, bFGF and G-CSF were below the range of the
standard curve and considered as insignificant. Thus
they are not presented on the graph. Media was col-
lected on day 0, 5, 10 and 15 and analyzed for the level
of growth factors by using the Human Growth Factor
(GF) 4-Plex Kit (Invitrogen, Carlsbad, CA). The concen-
tration of VEGF was undetectable at day 0 but became
detectable at day 5 and was significantly increased dur-
ing the 15-day measurement period (Figure 4). However,
none of the other growth factors including EGF were
detectable during the 15 days.
Treatment with Rapamycin, a potent mTOR/VEGF
inhibitor, dramatically inhibits proliferation of IH tumor
stem cells in vitro
As shown above, IH tumor stem cells were able to spe-
cifically secrete VEGF and this study indicates that
VEGF may play a significant role in tumor stem cell
growth. Should this hypothesis be correct, inhibition of
VEGF functions should inhibit IH stem cell growth
[30-32]. In fact, treatment of IH tumor stem cells with
Rapamycin leads to inhibition of the growth of IH stem
cells in our tumor sphere culture system. As shown in
Figure 4, three different concentrations of Rapamycin, 1
nM, 2 nM and 4 nM, all in a biologically significant
range, inhibited IH stem cell growth in a dose depen-
dent manner. At days 0, 3, 6, 10, tumor sphere samples
were collected, dissociated with collagenase IV, and the
number of cells counted. Treatment with Rapamycin
dramatically inhibited IH tumor stem cell growth.
In vivo mouse model
In order to generate an in vivo hemangioma mouse
model, and to determine whether IH stem cells have the
ability to generate tumors in immunodeficient mice, dis-
sociated IH tumor sphere cells were resuspended in
Matrigel and injected subcutaneously into 6-week-old
NOD/SCID mice (10
6 cells/200 μl Matrigel/animal).
Tumors were produced and as shown in Figure 5, all
the tumors were GLUT1 positive indicating an IH cell
of origin. Tumors exhibiting a proliferative cell phase
were positive for CD31, an endothelial cell marker.
These results demonstrated that IH stem cells can form
hemangiomas in vivo. Tumors visible on day 10 exhib-
ited mostly proliferative endothelial cells after H & E
staining. Twenty days after injection, both blood vessels
and fatty tissue became visible in H & E sections
although proliferating cells were still present. By day 30,
most of the cells injected into the animal had differen-
tiated, and tumor involution occurred, with a high per-
centage of fatty tissue present (See Figure 5). This 30
day cycle of in vivo tumorigenis in mice represents the
5-9 year process seen in human cases of IH. The appar-
ent faithful replication of hemangioma growth in this IH
stem cell-induced in vivo hemangioma mouse model
suggests that this system can be used as a tool to dis-
cover novel therapeutics specifically targeting IHs.
Discussion
Infantile hemangiomas are the most common tumors of
childhood and the head and neck region is most com-
monly affected. They may grow rapidly and cause
destruction of normal anatomic structures, leading to
severe disfigurement. Some of these tumors respond to
medical therapy with beta-blockers. However, when this
therapy fails, surgical excision may be necessary. Nonin-
vasive therapies to debulk or eliminate these tumors
would be an important advance. The development of an
in vitro cell culture system and an animal model should
permit new insights into the biological processes
involved in the development and pathogenesis of IH.
The natural history of rapid proliferation during early
infancy and subsequent involution strongly suggests that
normal growth factors are regulating the growth and
expansion of these tumors. In contrast to many other
tumors which do not regress, IH is not naturally capable
of sustained tissue renewal or growth. There has been
speculation that the placenta may be the source of cells
that form the IH because of the similarities between the
expression of specific prot e i n ss u c ha sG L U T 1 ,a n d
RNA array expression profiles from IH and the placenta.
While the present studies cannot support or refute the
placental origin of IH stem cells, they show that stem
cell markers such as SALL4 and CD133 can be identi-
fied in IH. The tumors from younger patients with
more proliferative IH contain more cells immunochemi-
cally staining for these early stem cell markers than
tumors excised from older children which have more
adipose and fibrous connectivet i s s u ec h a r a c t e r i s t i co f
the involuting IH. Based on this study, the involution
process is accompanied by, and related to a decrease in
the number of IH stem cells.
IH stem cells have been isolated from IHs surgically
removed from patients and grown to purity as tumor
spheres in selective media. When grown in stem cell
media the fibroblasts that initially grow out of the
minced tissue are depleted and the resulting cell popula-
tion consists only of IH tumor stem cells, which form
tumor spheres. Complex protocols for the purification
of tumor stem cells have been described utilizing
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Page 7 of 11Figure 4 IH tumor sphere specifically secrete VEGF and Rapamycin, an mTOR/VEGF inhibitor inhibits proliferation of IH tumor stem
cells. A, Concentration of VEGF secreted from tumor spheres at different days of cell culture. Every 5 days media was collected and the
concentration of VEGF was evaluated by multiplex Luminex assay. Three independent measurements were performed. The result indicates that
IH tumor spheres continuously secreted VEGF and that the secreted growth factor may be involved in the proliferation of the tumor spheres. B,
Inhibition of growth of tumor spheres by Rapamycin. Three different concentration of Rapamycin, 1 nM, 2 nM and 4 nM was used. At days 0, 3,
6 and 10, a sample of tumor spheres was collected, dissociated with collagenase IV and number of cells were counted.
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Page 8 of 11Figure 5 In vivo hemangioma mouse model. Tissue sections of tumors formed after injection of cells from IH tumor spheres into mice were
examined after 10, 20 and 30 days. (a, b, e, f, i, j) Hematoxylin and Eosin Staining (c, d, g, h, k, i) Immunofluorescent staining with anti-CD31 and
anti-GLUT1 antibodies. Secondary antibody only (m) and mouse fat tissue staining with GLUT-1 (n) were used as negative control. Human
hemangioma staining with GLUT-1(o) and CD31 (p) were used as positive controls.
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Page 9 of 11methods such as FACs sorting and immunomagnetic
purification strategies [12]. In contrast, the preparation
of purified stem cell from IH tumors described here by
growth in selective media is quite simple.
The cells from the IH tumor spheres have been shown
to express stem cell markers and GLUT1-positive staining
(Figure 2). The tumor spheres can be dissociated into sin-
gle cells and can undergo many generations of growth in
vitro. The dissociated cells can be reseeded to form new
tumor spheres. This extensive multi-generational growth
after multiple rounds of subculturing supports the concept
that the IH stem cells are not preprogrammed to age and
die within the in vitro culture system.
IH tumor sphere cells also express VEGF. VEGF is
commonly expressed by tumor cells, presumably due to
hypoxia, and aids in creating an optimal environment
for growing tumors by increasing angiogenesis. Anti-
VEGF therapies, including monoclonal antibodies such
as bevacizumab (Avastin), antibody derivatives such as
ranibizumab (Lucentis), or orally-available small mole-
cules that inhibit the tyrosine kinases stimulated by
VEGF: sunitinib (Sutent), sorafenib (Nexavar), axitinib,
and pazopanib, have become well accepted chemothera-
peutic agents. The sensitivity of IH tumor sphere cells
to rapamycin implies that anti-VEGF therapy should be
tested in the animal model described here, with poten-
tial eventual application for therapy.
When the tumor spheres are replated in medium con-
taining serum, the spheres show an outgrowth of cells
that are endothelial cells and their precursors (Figure 2),
suggestive of the angiogenic differentiation seen in IH
tumors. Cells derived from tumor spheres have been
placed subcutaneously in immune-suppressed mice
where they form tumors that recapitulate the histologi-
cal pattern of IH removed from patients. The tumors
removed from the inoculated mice stained with GLUT1
and CD31 confirming that they are of human origin and
are similar to human IHs (Figure 5).
These IH xenografts were removed from the mice and
studied at 10, 20 and 30 days post inoculation. Histolo-
gical studies showed that at 10 days there was a tumor
formed that was composed of proliferating endothelial
cells and blood vessels consistent with a proliferative IH,
at 20 days there was less proliferation and some fat and
fibrous connective tissue consistent with the beginning
of involution, at 30 days most of the vascular tissue was
gone and there was a predominance of adipose and con-
nective tissue (Figure 5). This temporal sequence mimics
the natural course IH undergoes in humans.
The development of a mouse xenograft of IH and the
establishment of an in vitro tissue culture system for pro-
pagating IH stem cell will be critical for assessing both
host effects and the efficacy of drug therapies. The stem
cell of the IH can now be studied for genetic aberrations
as well as epigenetic modifications caused by the loss or
gain of host growth factors or exogenous agents.
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